[PDF][PDF] β‐catenin deficiency in hepatocytes aggravates hepatocarcinogenesis driven by oncogenic β‐catenin and MET
Both activating and inactivating mutations in catenin β1 (ctnnb1), which encodes β‐catenin,
have been implicated in liver tumorigenesis in humans and mice, although the underlying …
have been implicated in liver tumorigenesis in humans and mice, although the underlying …
Hepatocellular Carcinoma: Old and Emerging Therapeutic Targets
Simple Summary Liver cancer is one of the most difficult solid tumors to treat and is
responsible for one-third of cancer-related deaths worldwide. In particular, the quest for …
responsible for one-third of cancer-related deaths worldwide. In particular, the quest for …
The hepatocyte growth factor/mesenchymal epithelial transition factor axis in high-risk pediatric solid tumors and the anti-tumor activity of targeted therapeutic agents
M Grundy, A Narendran - Frontiers in pediatrics, 2022 - frontiersin.org
Clinical trials completed in the last two decades have contributed significantly to the
improved overall survival of children with cancer. In spite of these advancements, disease …
improved overall survival of children with cancer. In spite of these advancements, disease …
[HTML][HTML] Hepatoblastoma: current knowledge and promises from preclinical studies
DF Calvisi, A Solinas - Translational Gastroenterology and …, 2020 - ncbi.nlm.nih.gov
The survival rate for patients with metastatic hepatoblastoma (HB) is steadily increased in
the last thirty years from 27% to 79%. These achievements result from accurate risk …
the last thirty years from 27% to 79%. These achievements result from accurate risk …
Microenvironment of a tumor-organoid system enhances hepatocellular carcinoma malignancy-related hallmarks
Y Wang, K Takeishi, Z Li, E Cervantes-Alvarez… - …, 2017 - Taylor & Francis
Organ-like microenviroment and 3-dimensional (3D) cell culture conformations have been
suggested as promising approaches to mimic in a micro-scale a whole organ cellular …
suggested as promising approaches to mimic in a micro-scale a whole organ cellular …
Establishment of a novel mouse hepatocellular carcinoma model for dynamic monitoring of tumor development by bioluminescence imaging
X Cao, Y Zhang, Q Zhou, S Sun, M He, X Wang… - Frontiers in …, 2022 - frontiersin.org
In this study, a novel mouse model of hepatocellular carcinoma (HCC) was established by
simultaneously knocking out Pten and p53 suppressor genes and overexpressing c-Met …
simultaneously knocking out Pten and p53 suppressor genes and overexpressing c-Met …
Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy
P Song, Z Gao, Y Bao, L Chen, Y Huang, Y Liu… - Journal of Hematology & …, 2024 - Springer
The Wnt/β-catenin signaling pathway plays a crucial role in various physiological processes,
encompassing development, tissue homeostasis, and cell proliferation. Under normal …
encompassing development, tissue homeostasis, and cell proliferation. Under normal …
Scaffolding protein IQGAP1 is dispensable, but its overexpression promotes hepatocellular carcinoma via YAP1 signaling
ER Delgado, HL Erickson, J Tao… - … and cellular biology, 2021 - Am Soc Microbiol
ABSTRACT IQ motif-containing GTPase-activating protein 1 (IQGAP1) is a ubiquitously
expressed scaffolding protein that is overexpressed in a number of cancers, including liver …
expressed scaffolding protein that is overexpressed in a number of cancers, including liver …
Preclinical mouse models of hepatocellular carcinoma: An overview and update
CY Gu, TKW Lee - Experimental cell research, 2022 - Elsevier
Hepatocellular carcinoma (HCC) is by far the most common histological subtype of primary
liver cancer. HCC often originates from chronic liver injuries and inflammation, subsequently …
liver cancer. HCC often originates from chronic liver injuries and inflammation, subsequently …
[HTML][HTML] The effect of selective c-MET inhibitor on hepatocellular carcinoma in the MET-active, β-catenin-mutated mouse model
Simultaneous mutations in CTNNB1 and activation of c-MET occur in 9%–12.5% of patients
with hepatocellular carcinoma (HCC). Coexpression of c-MET-V5 and mutant β-catenin-Myc …
with hepatocellular carcinoma (HCC). Coexpression of c-MET-V5 and mutant β-catenin-Myc …